Mark McHale, MD
Frontline varlitinib (ASLAN001) added to mFOLFOX6 was not found to significantly reduce tumor size after 12 weeks of therapy compared with mFOLFOX6 alone in patients with HER1/HER2 co-expressing advanced or metastatic gastric cancer, missing the primary endpoint of a phase II study, according to ASLAN Pharmaceuticals, the company developing the pan-HER inhibitor.
ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer. Aslan Pharmaceuticals. Published January 14, 2019. https://bit.ly/2stwaIZ?rel=0" . Accessed January 14, 2019.
... to read the full story